Table 3.
Univariable and multivariable regression analysis of response and PFS to Anti-CTLA4 plus anti-PD1 combination treatment
| Best Response (DCR) | ||||||
| Parameters | Univariable Logistic Regression | Multivariable Logistic Regression | ||||
| HR (95% CI) | p | HR (95% CI) | p | |||
| Age* (<55 Vs > 55 Years) |
0.28 (0.07–1.12) | 0.073 | ||||
| Gender (Male Vs Female) |
0.44 (0.12–1.57) | 0.208 | ||||
| Braf (Braf wt Vs Braf mt) |
1.45 (0.38–5.54) | 0.583 | ||||
| Prior Systemic Therapy (No Vs Yes) | 0.48 (0.13–1.72) | 0.264 | ||||
| Tumor Stage (M0, M1a, M1b Vs M1c, M1d) |
0.63 (0.15–2.52) | 0.514 | ||||
| Liver Metastases (No Vs Yes) |
0.80 (0.22–2.84) | 0.735 | ||||
| Brain Metastses (No Vs Yes) |
1.87 (0.47–7.45) | 0.372 | ||||
| LDH (Normal Vs Elevated) |
0.26 (0.07–0.98) | 0.048 | 0.28 (0.05–1.43) | 0.126 | ||
| Hemoglobin* (<12.6 Vs > 12.6 g/dl) |
8.14 (1.95–33.86) | 0.004 | 5.50 (1.14–26.45) | 0.033 | ||
| sPD1* (<167 Vs >167 pg/ml) |
0.18 (0.04–0.75) | 0.019 | 0.17 (0.03–0.88) | 0.036 | ||
| Progression-Free Survival (PFS) | ||||||
| Parameters | Univariable Cox Regression | Multivariable Cox Regression | ||||
| HR (95% CI) | p | HR (95% CI) | p | |||
| Age (<55 Vs > 55 Years) |
0.78 (0.36–1.70) | 0.541 | ||||
| Gender (Male Vs Female) |
0.53 (0.24–1.16) | 0.114 | ||||
| Braf (Braf wt Vs Braf mt) |
0.77 (0.35–1.71) | 0.530 | ||||
| Prior Systemic Therapy (No Vs Yes) | 0.63 (0.29–1.34) | 0.231 | ||||
| Tumor Stage (M0, M1a, M1b Vs M1c, M1d) |
1.04 (0.46–2.33) | 0.915 | ||||
| Liver Metastases (No Vs Yes) |
0.76 (0.35–1.64) | 0.497 | ||||
| Brain Metastses (No Vs Yes) |
1.55 (0.65–3.68) | 0.315 | ||||
| LDH (Normal Vs Elevated) |
0.84 (0.39–1.83) | 0.675 | ||||
| Hemoglobin (<12.6 Vs > 12.6 g/dl) |
2.27 (1.05–4.90) | 0.036 | 2.24 (1.02–4.89) | 0.043 | ||
| sPD1 (<167 Vs >167 pg/ml) |
0.44 (0.20–0.98) | 0.046 | 0.43 (0.19–0.95) | 0.038 | ||
*Age, hemoglobin, and sLAG3 were dichotomized for regression analysis based on ROC cutoff values with the response as an event